X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8388) 8388
Magazine Article (32) 32
Newspaper Article (21) 21
Book Chapter (16) 16
Newsletter (10) 10
Government Document (4) 4
Book Review (3) 3
Reference (2) 2
Trade Publication Article (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7021) 7021
male (4594) 4594
stroke (4263) 4263
female (4256) 4256
aged (3219) 3219
middle aged (2934) 2934
risk factors (2533) 2533
hemorrhage - chemically induced (2045) 2045
animals (1711) 1711
treatment outcome (1657) 1657
anticoagulants - adverse effects (1598) 1598
stroke - prevention & control (1577) 1577
adult (1558) 1558
aged, 80 and over (1429) 1429
cardiac & cardiovascular systems (1369) 1369
clinical neurology (1313) 1313
stroke - chemically induced (1264) 1264
risk (1242) 1242
peripheral vascular disease (1164) 1164
warfarin (1156) 1156
atrial fibrillation - drug therapy (1106) 1106
stroke - etiology (1106) 1106
atrial fibrillation (1091) 1091
neurosciences (1057) 1057
time factors (1009) 1009
anticoagulants - therapeutic use (984) 984
stroke - drug therapy (962) 962
mortality (935) 935
atrial fibrillation - complications (926) 926
risk assessment (924) 924
anticoagulants (917) 917
medicine, general & internal (905) 905
therapy (882) 882
retrospective studies (855) 855
cerebral hemorrhage - chemically induced (844) 844
abridged index medicus (829) 829
rats (826) 826
anticoagulants - administration & dosage (813) 813
prevention (774) 774
fibrinolytic agents - adverse effects (733) 733
ischemia (732) 732
warfarin - adverse effects (726) 726
hemorrhage (719) 719
stroke - epidemiology (717) 717
administration, oral (711) 711
pharmacology & pharmacy (707) 707
care and treatment (700) 700
platelet aggregation inhibitors - adverse effects (697) 697
aspirin (659) 659
analysis (621) 621
drug therapy (600) 600
neurology (598) 598
prospective studies (596) 596
management (586) 586
disease models, animal (581) 581
dabigatran (578) 578
stroke volume - drug effects (562) 562
tissue plasminogen activator - adverse effects (529) 529
incidence (528) 528
research (523) 523
brain (504) 504
follow-up studies (502) 502
health aspects (495) 495
platelet aggregation inhibitors - therapeutic use (487) 487
warfarin - therapeutic use (486) 486
randomized controlled trials as topic (482) 482
hematology (481) 481
dose-response relationship, drug (476) 476
intracranial hemorrhages - chemically induced (470) 470
safety (462) 462
anticoagulation (460) 460
hypertension (460) 460
brain ischemia - drug therapy (459) 459
cardiovascular (458) 458
bleeding (457) 457
drug therapy, combination (451) 451
patients (451) 451
medicine & public health (447) 447
aspirin - adverse effects (438) 438
fibrinolytic agents - therapeutic use (438) 438
intracerebral hemorrhage (436) 436
cardiovascular diseases (432) 432
thromboembolism (432) 432
mice (429) 429
stroke prevention (424) 424
cardiovascular disease (421) 421
thrombolytic therapy - adverse effects (412) 412
atrial-fibrillation (411) 411
thrombolysis (409) 409
stroke - diagnosis (405) 405
cohort studies (398) 398
cardiology (394) 394
myocardial infarction (389) 389
thrombosis (385) 385
rivaroxaban (383) 383
stroke volume (383) 383
adolescent (381) 381
acute ischemic-stroke (378) 378
hemorrhage - epidemiology (374) 374
ischemic-stroke (370) 370
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8138) 8138
German (97) 97
French (71) 71
Spanish (50) 50
Japanese (43) 43
Russian (19) 19
Italian (18) 18
Portuguese (15) 15
Swedish (15) 15
Polish (12) 12
Dutch (10) 10
Chinese (9) 9
Norwegian (8) 8
Hungarian (7) 7
Czech (6) 6
Danish (6) 6
Croatian (3) 3
Hebrew (3) 3
Bulgarian (2) 2
Finnish (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2016, Volume 67, Issue 20, pp. 2395 - 2410
.... SAMS is the most frequent SAS, and mild myalgia may affect 5% to 10% of statin users. Clinically important muscle symptoms, including rhabdomyolysis and statin-induced necrotizing autoimmune myopathy... 
Cardiovascular | Internal Medicine | rhabdomyolysis | skeletal muscle | interstitial lung disease | myopathy | C-REACTIVE PROTEIN | RANDOMIZED CONTROLLED-TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | FORCE 2014 UPDATE | PRIMARY-PREVENTION TRIAL | INDUCED MUSCLE TOXICITY | INTERSTITIAL LUNG-DISEASE | CENTRAL-NERVOUS-SYSTEM | OF-THE-LITERATURE | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | Liver Function Tests | Sleep Wake Disorders - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - immunology | Myalgia - chemically induced | Humans | Hyperlipidemias - drug therapy | Risk Factors | Lung Diseases, Interstitial - chemically induced | Tendon Injuries - chemically induced | Necrosis - chemically induced | Brain - drug effects | Rupture - chemically induced | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Stroke - chemically induced | Cognition Disorders - etiology | Depression - chemically induced | Rhabdomyolysis - chemically induced | Antibodies - blood | Diabetes Mellitus - chemically induced | Acute Kidney Injury - chemically induced | Muscular Diseases - chemically induced | Testosterone - blood | Autoimmune Diseases - chemically induced | Hyperlipidemias - complications | Viral antibodies | Complications and side effects | Enzymes | Thiols | Antibodies | Diabetes | Cardiology | Statins | Cardiovascular agents | Creatine kinase | Muscles | Creatine | Respiratory tract diseases | Studies | Musculoskeletal system | Genotype & phenotype | Mortality | Clinical trials | Lipids | Clinical medicine
Journal Article
The Lancet. Haematology, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Infections - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced
Journal Article
by Baigent, Colin and Bhala, N and Emberson, J and Merhi, A and Abramson, S and Arber, N and Baron, J.A and Bombardier, C and Cannon, C and Farkouh, M.E and FitzGerald, G.A and Goss, P and Halls, H and Hawk, E and Hawkey, C and Hennekens, C and Hochberg, M and Holland, L.E and Kearney, P.M and Laine, L and Lanas, A and Lance, P and Laupacis, A and Oates, J and Patrono, C and Schnitzer, T.J and Solomon, S and Tugwell, P and Wilson, K and Wittes, J and Adelowo, O and Aisen, P and Al-Quorain, A and Altman, R and Bakris, G and Baumgartner, H and Bresee, C and Carducci, M and Chang, D.-M and Chou, C.-T and Clegg, D and Cudkowicz, M and Doody, L and Miedany, Y.El and Falandry, C and Farley, J and Ford, L and Garcia-Losa, M and Gonzalez-Ortiz, M and Haghighi, M and Hala, M and Iwama, T and Jajic, Z and Kerr, D and Kim, H.-S and Kohne, C and Koo, B.-K and Martin, B and Meinert, C and Muller, N and Myklebust, G and Neustadt, D and Omdal, R and Ozgocmen, S and Papas, A and Patrignani, P and Pelliccia, F and Roy, V and Schlegelmilch, I and Umar, A and Wahlstrom, O and Wollheim, F and Yocum, S and Zhang, X.Y and Hall, E and McGettigan, P and Midgley, R and Moore, R.A and Philipson, R and Curtis, S and Reicin, A and Bond, J and Moore, A and Essex, M and Fabule, J and Morrison, B and Tive, L and Bhala, N and Davies, K and Emberson, J and Halls, H and Holland, L.E and Kearney, P.M and Merhi, A and Patrono, C and Wilson, K and Yau, F and unav and Coxib and traditional NSAID Trialists' (CNT) Collaboration and Coxib Traditional NSAID Trialists
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 382, Issue 9894, pp. 769 - 779
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2017, Volume 76, Issue 3, pp. 432 - 440.e17
Journal Article
Circulation. Heart failure, ISSN 1941-3297, 2016, Volume 9, Issue 1, pp. e002314 - e002314
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2010, Volume 102, Issue 1, pp. 14 - 25
Due to the aging of the populations of developed countries and a common occurrence of risk factors, it is increasingly probable that a patient may have both... 
DOXORUBICIN-INDUCED CARDIOTOXICITY | TRASTUZUMAB-RELATED CARDIOTOXICITY | ONCOLOGY | SPORADIC COLORECTAL ADENOMAS | VASCULAR-DISRUPTING AGENTS | TYROSINE KINASE INHIBITOR | N-ACETYLCYSTEINE | DAUNORUBICIN-INDUCED CYTOTOXICITY | HIGH-DOSE CHEMOTHERAPY | EARLY BREAST-CANCER | ATRIAL-FIBRILLATION | Atrial Fibrillation - chemically induced | Cardiovascular Diseases - prevention & control | Humans | Patient Care Team | Atrial Fibrillation - physiopathology | Ventricular Dysfunction, Left - chemically induced | Flavonoids - therapeutic use | Cardiotonic Agents - therapeutic use | Venous Thromboembolism - prevention & control | Cardiovascular System - physiopathology | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Antineoplastic Agents - adverse effects | Hypertension - chemically induced | Hypertension - prevention & control | Polyphenols | Free Radical Scavengers - therapeutic use | Acetylcysteine - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Cardiovascular Diseases - diagnosis | Heart - physiopathology | Cardiovascular Diseases - physiopathology | Stroke Volume - drug effects | Anticoagulants - therapeutic use | Cardiovascular System - drug effects | Hypertension - physiopathology | Ventricular Dysfunction, Left - physiopathology | Ventricular Dysfunction, Left - prevention & control | Cardiovascular Diseases - microbiology | Animals | Blood Coagulation - drug effects | Venous Thromboembolism - physiopathology | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Phenols - therapeutic use | Venous Thromboembolism - chemically induced | Heart - drug effects | Cardiovascular Diseases - chemically induced | Atrial Fibrillation - prevention & control | Antimitotic agents | Complications and side effects | Aging | Physiological aspects | Dosage and administration | Research | Cardiovascular diseases | Antineoplastic agents | Risk factors | Index Medicus | Review
Journal Article
COPD: Journal of Chronic Obstructive Pulmonary Disease, ISSN 1541-2563, 2013, Volume 10, Issue 4, pp. 500 - 510
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 3, pp. 203 - 212
Adults with vascular disease were treated with a statin to lower LDL cholesterol and were assigned to receive either extended-release niacin plus laropiprant... 
NICOTINIC-ACID | LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | METABOLIC SYNDROME | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | EFFICACY | SAFETY | PLACEBO-CONTROLLED TRIAL | NIACIN/LAROPIPRANT | DYSLIPIDEMIA | Follow-Up Studies | Humans | Middle Aged | Male | Hypercholesterolemia - drug therapy | Indoles - administration & dosage | Infection - chemically induced | Niacin - administration & dosage | Treatment Failure | Musculoskeletal Diseases - chemically induced | Niacin - adverse effects | Cholesterol, LDL - blood | Female | Hypolipidemic Agents - adverse effects | Atherosclerosis - drug therapy | Double-Blind Method | Risk Factors | Indoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Diabetes Mellitus - chemically induced | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Drug Combinations | Dose-response relationship (Biochemistry) | Laropiprant | Blood circulation disorders | Care and treatment | Dosage and administration | Niacin | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Heart attacks | Risk groups | Diabetes mellitus | Cardiovascular disease | Low density lipoprotein | Cholesterol | Musculoskeletal system | Vascular diseases | Arteriosclerosis | Vitamin B | Skin | Lipoproteins (high density) | Drug dosages | Statins
Journal Article